1. In Vivo
  2. >>Innovation

Trex Medical's Story

Trex Medical got a bit of good news in February, when the FDA said that it considers the company's 510K submission for clearance of a digital mammography system to be active. That may not seem like much, but the company's been in a lot of hot water lately. In December, much to the surprise of many, the FDA rejected the company's initial application for its digital mammography system, saying the data didn't support the company's contention that its digital mammography equipment was equivalent to standard mammography. Then, the company had to restate its fourth quarter and year-end results and its long-time CEO, Hal Kirshner, resigned. A new CEO was appointed in January, Michael Webb, a former Picker International executive.

Trex Medical Corp. , a leading provider of mammography and X-ray equipment, got a bit of good news in February, when the FDA said that it considers the company's 510K submission for clearance of a digital mammography system to be "active." That may not seem like much, except that the company has been in so much hot water lately.

Only last December, the agency categorized the filing for digital mammography, which Trex submitted more than a year ago, to be "withdrawn." This was a blow for Trex, which spent...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Innovation

More from In Vivo

Medtech Innovators Court London-Based Investors At BioWales 2025

 
• By Ashley Yeo

BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By David Wild

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.

UK Bets On Regulatory Innovation As Competitive Advantage In Synthetic Biology

 
• By David Wild

The UK government has prioritized synthetic biology and created a "concierge service" for biotechs just as the US cuts science funding.